We're at the #OTS23 Meeting this week -- excited to share updates on our application of #AI to the discovery and development of #oligonucleotide and #RNA therapeutics.
Stop by to learn more at the following 4 posters.
https://t.co/mCM9aAxpS6
Découvrez ce nouveau travail étonnant du sponsor bronze de Vecteur @deepgenomics et du cofondateur de Vecteur, Brendan Frey. Comme indiqué ci-dessous, l'équipe a développé le premier modèle de base pour les thérapies ARN 👇
Check out this amazing new work from Vector Bronze Sponsor @deepgenomics & Vector co-founder Brendan Frey. As outlined below the team developed the first foundation model for RNA therapeutics 👇
The first foundation #AI model for RNA
https://t.co/aNsRMbEuAu
Predicting protein and microRNA binding sites, tissue-specific expression, variants -> gene expression and splicing ++
@deepgenomics@frey_brendan and colleagues
16/16 We hope that our model BigRNA, and more RNA foundation models like it, will continue to transform the fields of disease variant interpretation and personalized therapeutics
We are thrilled to share our manuscript ‘An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics’ as a preprint! 🧵
https://t.co/izQ0eV9bzc
15/16 Here it’s important to have accurate predictions to lower the number of drugs screened. We analyzed variants in ClinVar that are amenable to this approach.